Lut Ming Cheng
JPMorgan Chase & Co, Research Division
Good afternoon, everyone. Thanks for joining us for another session at the 44th JPMorgan Healthcare Conference. I’m Brian Cheng. I’m one of the senior biotech analysts here at the firm. On stage, we have Mike Weiss, who is the CEO of TG Therapeutics.
I’ll now pass the mic to their CEO for a short presentation, followed by a live audience Q&A. Mike, the stage is yours.
Michael Weiss
Chairman, CEO & President
Great. Thank you, Brian, and thanks, everyone, for joining us. I’m going to get started here. Just before I do, let me just mention that I will make some forward-looking statements. For those of you who are interested, I do encourage you to review our public disclosure documents available on the line.
Just a way of quick background for those of you who may not be that familiar with TG Therapeutics. We were founded in 2012 with a focus on B-cell-mediated diseases. These can range from autoimmune diseases to neuroinflammatory as well as cancer. But today, we’re focused primarily on MS. We have one approved drug, BRIUMVI for multiple sclerosis, which is approaching blockbuster status. We have 2 pivotal trials ongoing to expand the utilization and total addressable market for BRIUMVI, and we have 3 programs under development.
So there it is BRIUMVI. This is our approved anti-CD20 monoclonal antibody. It was approved in late December of ’22 and launched in January of ’23, so a little under 3 years ago. And — but not only is available in the U.S., but it’s available now globally. Our partners at
